Spotlight
Video

iwNHL 2015: Duvelisib, dual inhibitor of PI3K delta and PI3K gamma, for indolent non-Hodgkin lymphoma

VJHemOnc has 1608 videos Subscribe Here

Loading........
Description: At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Ian Flinn, MD, of Tennessee Oncology, Nashville, TN, discusses the clinical development of duvelisib, a dual inhibitor of phosphoinositide 3-kinase (PI3K) delta and PI3K gamma, for the treatment of patients with indolent non-Hodgkin lymphoma (iNHL). Duvelisib has demonstrated promising clinical activity in patients with relapsed/refractory iNHL and ongoing clinical trials are investigating duvelisib alone and in combination for this disease.

—————

The Video Journal of Hematological Oncology (VJHemOnc) is an independent, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve understanding and awareness of hematological malignancies.

Website: http://www.vjhemonc.com/...
Twitter: https://twitter.com/VJHemOn...
Facebook: https://www.facebook.com/vj...
LinkedIn: https://www.linkedin.com/co...
Shared By : VJHemOnc
Posted on : 11/22/15
Added : 4 years ago